SOLID TUMORS

This is the first human study of an experimental drug called QTX3034 for people with advanced solid tumors that have a specific genetic change called KRASG12D. The trial aims to find the safest dose and see how well the drug works, either alone or combined with an existing cancer…

This is the first study in people to test a new drug called AUBE00 for advanced solid tumors. It aims to find a safe dose, see how the body processes the drug, and check for any early signs it might help shrink tumors. The study is for adults with certain advanced cancers who hav…

This is an early-stage study to test the safety and side effects of a new drug called HS-20110 in adults with advanced solid tumors. Researchers will give the drug to participants and closely monitor how their bodies handle it and if it shows any signs of shrinking their tumors. …

This is the first study testing the experimental drug DPTX3186 in people with advanced solid tumors that have no other treatment options. The main goals are to check if the drug is safe and how the body processes it in about 40 participants. Researchers will also look for early s…

This study is testing a new drug called HRS-7058, given in combination with other anti-cancer drugs, in adults with solid tumors. The main goals are to find a safe and effective dose, check for side effects, and see if the treatment can shrink tumors. It will enroll about 100 par…

This study is tracking the long-term safety and effectiveness of the cancer drug pembrolizumab (Keytruda) in patients who were already receiving it in previous Merck trials. It will follow 3,500 people with various solid tumors or blood cancers to see how they do over an extended…

This is the first human study of an experimental antibody drug called CBA-1205 for people with advanced solid tumors that haven't responded to standard treatments. The trial will test the drug's safety and find the right dose in 66 adults and children with various cancers includi…

This study is testing a new drug called SHR-4610 injection in people with advanced solid tumors that have stopped responding to standard treatments. Researchers want to find the safest and most effective dose, check how the body processes the drug, and see if it helps control the…

This is the first human study of an experimental drug called INCA036873 for people with advanced cancers that have stopped responding to standard treatments. The main goal is to find the safest dose and understand how the drug moves through the body. The study will enroll 280 adu…

This study is testing a new drug called S-531011 for people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug, given alone or with other cancer therapies, can shrink tumors. It is for adults who…

This is an early-stage study testing a new type of cell therapy for people with advanced solid tumors that have stopped responding to standard treatments. Doctors are using specially engineered immune cells from donated cord blood, designed to target a protein called TROP2 found …

This study is testing a personalized cancer vaccine made from the unique mutations found in a patient's own tumor. The goal is to see if this custom vaccine, given with other immune-boosting drugs, is safe and can help control advanced or high-risk cancers. It is for adults with …

This study is testing an experimental drug called M9140 in people with advanced gastric, lung, or pancreatic cancer that has stopped responding to standard treatments. The trial aims to see if M9140 can shrink tumors and is safe for patients. It will enroll about 250 adults whose…

This early-stage study is testing a new drug called XB371 in people with advanced solid tumors that have spread or returned after treatment. Researchers want to find the safest dose, check for side effects, and see how the body processes the medication. The study will enroll abou…

This global trial tests whether matching cancer treatments to a patient's specific tumor genetics works better than standard approaches. It's for people with advanced solid tumors that have spread or can't be surgically removed. Participants receive drugs specifically chosen base…

This early-stage study is testing an experimental drug called ZL-1310 in adults with advanced solid tumors that have continued to grow despite previous treatment. The main goals are to check if the drug is safe and to see if it helps shrink tumors. About 112 people with specific …

This is the first study testing the experimental drug JR8603 in people. It aims to find a safe dose and see if it helps control advanced solid tumors, particularly stomach, esophageal junction, and colorectal cancers, when standard treatments have stopped working. The study will …

This is the first study in people to test a new drug called INCB161734, which is designed to target a specific genetic change (KRAS G12D mutation) found in some advanced solid tumors. The main goals are to find a safe dose and see how well the drug is tolerated, both by itself an…

This is the first study in people to test a new drug called BI 1703880 when given with an existing immunotherapy drug, ezabenlimab. The main goal is to find the safest and most effective dose of the new combination for adults with advanced solid tumors that have not responded to …

This study is testing whether combining two drugs, Envafolimab and Lenvatinib, can help control advanced cancers like lung, kidney, and liver cancer that have progressed after standard treatments. The goal is to see if this combination is safe and can shrink tumors better than cu…

This early-stage study is testing a new drug called RC278 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest and most effective dose and to see if the drug helps shrink tumors. The trial will enroll about 3…

This study is testing whether adding an experimental drug called DCSZ11 to standard cancer treatments is safe and effective for people with advanced solid tumors that have spread. Researchers will enroll 9 adult patients with specific types of cancer to see how well the combinati…

This early-stage study is testing a new type of cancer treatment called TX103 CAR-T cell therapy in adults with advanced solid tumors that have a specific protein marker. The main goals are to check if the treatment is safe, find the right dose, and see if it shows any signs of f…

This early-stage trial is testing a new drug called ABL103, given alongside an existing immunotherapy (pembrolizumab) and sometimes with chemotherapy. It aims to see if this combination is safe and can help control advanced solid tumors that have stopped responding to standard tr…

This is the first study in people testing PEP08, a new oral cancer drug, for patients with advanced solid tumors that have a specific genetic change called MTAP deletion. The main goals are to find safe doses, see how the body processes the drug, and look for early signs that it …

This early-stage study is testing a new drug called INCB123667, both alone and in combination with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapies. The main goals are to find safe doses, understand how the drug wor…

This is an early-stage study testing a new drug called BL-M24D1 in patients with advanced gastrointestinal cancers and other solid tumors that have spread. The main goal is to find the safest dose and see how the body processes the drug. Researchers will also look for early signs…

This early-stage study is testing a new, flavored, oral version of a chemotherapy drug called irinotecan (named Orotecan®) in children and young adults whose solid tumors have come back. The main goals are to find a safe and effective dose and to see how the body processes the dr…

This is the first study in humans testing a new cancer drug called DS3610a. It aims to find a safe and tolerable dose for people with advanced solid tumors that have stopped responding to standard treatments. The study will enroll about 70 participants to monitor side effects and…

This is the first study in people to test a new drug called AB521 (casdatifan). The main goal is to find safe doses and see how the body processes the drug. It will be tested alone and in combinations for people with advanced kidney cancer and other solid tumors that have not res…

This is the first study in humans of a new drug called INCA33890 for people with advanced or spreading solid tumors. Researchers will test different doses in 408 participants to find the safest amount and see how the body processes the drug. The main goals are to understand side …

This study provides continued access to the cancer drugs encorafenib and/or binimetinib for patients who were already taking them in earlier clinical trials and are still benefiting. It allows these patients to keep receiving the same treatment for up to about 5 years while docto…

This is a first-in-human study to test the safety and early effectiveness of a new radioactive drug called Lutetium BL-ARC001. It is for adults with advanced gastrointestinal cancers or other solid tumors that have spread or cannot be surgically removed. The main goals are to fin…

This trial is testing whether combining the experimental drug DB-1311 with one of two other drugs (BNT327 or DB-1305) is safe and effective for treating advanced solid tumors that have spread or returned. It will enroll about 492 adults with specific advanced cancers, including l…

This is the first study in people testing a new drug called HRS-6208 for patients with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and understand the drug's side effects in about 206 participants. Researchers wil…

This early-stage study is testing a new type of personalized cell therapy called B7H3 CAR-T in people with advanced solid tumors. Doctors will take a patient's own immune cells, modify them in a lab to better target their cancer, and then infuse them back. The main goals are to c…

This clinical trial is testing an experimental oral medication called JAB-30355 for adults with advanced solid tumors that have a specific genetic mutation called TP53 Y220C. The study aims to determine the safest dose and see if the drug can shrink tumors in patients who have al…

This is a first-in-human study to test the safety and find the right dose of a new experimental drug called BG-C0902 for people with advanced solid tumors. The drug is designed to target two specific proteins found on some cancer cells. Researchers will enroll about 63 participan…

This is the first human study of an experimental drug called HDM2017 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose, see how the drug moves through the body, and check for any early signs that it m…

This is the first human study of an experimental cancer drug called ZL-6201. The main goal is to find a safe dose and see how the body processes the drug in adults with advanced sarcoma or certain other solid tumors that have stopped responding to standard treatments. Researchers…

This early-stage study is testing a new oral medication called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will first determine the safest dose and then look for early signs that the drug can shrink tumors in spec…

This is the first study in people testing an experimental pill called TYRA-430. It aims to find a safe dose and see if it can help control advanced liver cancer and other solid tumors that have specific genetic changes in the FGF/FGFR pathway. The study will enroll about 100 adul…

This early-stage study is testing a new cell therapy called GK01, given alone or with chemotherapy, after surgery to remove solid tumors. The main goal is to see if the treatment is safe and how the body handles it in adults with cancers like pancreatic, bile duct, or stomach can…

This is the first human study of an experimental cancer drug called GEN1106 for people with advanced solid tumors, particularly bladder cancer that has spread. The trial aims to find safe doses and see if the drug helps shrink tumors in patients who have already tried standard tr…

This is the first study testing a new drug called 7MW4911 in people with advanced solid tumors that have stopped responding to other treatments. The main goals are to find the safest and most effective dose and to see if the drug shows early signs of helping shrink tumors. Resear…

This is a first-in-human study testing a new drug called BI 1831169 for adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the highest safe dose of the drug when given alone and when combined with an existing immunoth…

This study is testing a drug called ponatinib in children and teenagers (ages 1 to 18) whose cancers have come back or have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can help control various advanced cancers, including leukem…

This program provides early access to an investigational cancer drug called telisotuzumab adizutecan for people with solid tumors. It is for patients who have no other suitable treatment options and do not qualify for ongoing clinical trials. A doctor must determine if the potent…

This early-stage study is testing a new radioactive drug called Lutetium-177 BL-ARC001 in people with advanced lung, breast, head/neck, and other solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose, see how the body process…

This early-stage trial is testing a new oral drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatments. The main goal is to find a safe dose and see how well the body handles the drug. Researchers hope the medication can turn back on ce…

This study is testing whether a diabetes medication called dapagliflozin can protect the kidneys from damage caused by platinum-based chemotherapy. Researchers will give the drug or a placebo to 46 adults with solid tumors before and during their chemo. They will measure specific…

This study is testing an oral drug called plixorafenib (FORE8394) for people with advanced solid tumors or brain tumors that have specific changes in a gene called BRAF. The main goal is to see if the drug can shrink tumors and is safe for patients, including adults and children …

This early-stage trial is testing a new three-target antibody called SOA101 in people with advanced solid tumors that have stopped responding to standard treatments. The study will first determine safe dosage levels, then look for initial signs that the treatment might help contr…

This clinical trial is testing a new oral drug called ICP-723 in adults and adolescents with advanced solid tumors that cannot be surgically removed. The main goals are to find the safest dose, see how the body processes the drug, and check for any early signs that it might help …

This early-stage study is testing whether directly injecting an experimental treatment called VLPONC-01 into head and neck tumors is safe and can help shrink them. Researchers are enrolling 41 patients with advanced or surgically removable cancers to receive the injections, somet…

This study is testing the safety and how the body processes a drug called eflapegrastim in children with solid tumors or lymphoma. The drug is given alongside standard chemotherapy and aims to help the body rebuild white blood cells, which are crucial for fighting infections. The…

This study is a registry that will follow 1000 adults with solid tumors who receive a targeted treatment. The treatment involves delivering chemotherapy drugs directly to the tumor using a special catheter called RenovoCath. The main goal is to collect real-world information on t…

This study aims to find a way to predict which cancer patients might develop serious side effects from immunotherapy drugs. Researchers will compare blood samples from 300 cancer patients starting immunotherapy with samples from 40 people who have autoimmune diseases. They are lo…

This study aims to understand the genetic changes in cancer cells by analyzing leftover tumor tissue and a normal sample from patients. The goal is to identify specific mutations that might predict how a tumor will respond to certain drugs. Researchers will track how these genes …

This study aims to find biological markers (biomarkers) that may help predict how well a new drug combination works for people with advanced solid tumors. Researchers will test the drugs SAR444881 and cemiplimab in 40 participants and collect tissue and blood samples to look for …